Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Epcoritamab Plus R-mini-CHOP May Aid in Treatment of Elderly Patients with First-Line DLBCL

December 7th 2025

Epcoritamab plus R-mini-CHOP delivered deep responses with manageable safety in elderly, high-risk patients with newly diagnosed DLBCL.

Rusfertide Continues to Show Strong Results for Polycythemia Vera

December 6th 2025

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.

Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma

December 6th 2025

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC

December 6th 2025

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age

December 6th 2025

Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.

Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC

December 5th 2025

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence

December 5th 2025

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC

December 5th 2025

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

Updated FIREFLY-1 Data Further Support Tovorafenib as a SOC in R/R Pediatric Low-Grade Glioma

December 3rd 2025

Tovorafenib produced deep, durable responses in pLGG, with long treatment-free intervals and minimal tumor rebound after therapy.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Sequential ICV/IV C7R-GD2 CAR T-Cell Therapy Is Better Tolerated in Pediatric CNS Tumors

November 24th 2025

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases

November 23rd 2025

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma

November 23rd 2025

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23rd 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma

November 23rd 2025

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma

November 22nd 2025

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer

November 22nd 2025

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.